The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow. Sellas reports galinpepimut-S (GPS) vaccine extends median survival to 24 months in AML trial versus 14.7 months, plans FDA submission. Patients who received vaccine had median overall survival of 24 months, compared against 14.7 months among those given best treatment. It also reduced the risk of death by 41%.